Article Abstract

Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy

Authors: Fabiana Perna, Michel Sadelain

Abstract

Gardner et al. recently reported on two cases of mixed lineage leukemia (MLL)+ acute myeloid leukemia (AML) occurring after CD19 chimeric antigen receptor (CAR) therapy for MLL+ B-acute lymphoblastic leukemia (ALL) (1). This report provides new insights into mechanisms of immune escape from targeted immunotherapy and strategies to prevent their occurrence with adapted immune interventions.